Abstract
Adults aged over 50 years, and people aged 12–49 years who are immunocompromised, will be among those eligible to receive the newly approved monoclonal antibody (MAb) cocktail, Ronapreve (casirivimab and imdevimab; Roche Products Ltd), and could do so from this week, the Department of Health and Social Care (DHSC) has said. The eligibility criteria for […]
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
